Skip to main content

Advertisement

SpringerLink
Log in

Virologic and immunologic response to highly active antiretroviral therapy

  • Published:
Current Infectious Disease Reports Aims and scope Submit manuscript

Abstract

Highly active antiretroviral therapy (HAART) delays clinical progression to AIDS by suppressing viral replication, allowing the immune system to reconstitute. These virologic and immunologic consequences do not occur uniformly among HAART users; markers of HIV disease stage at the time of HAART initiation are critical determinants of the progression while under HAART. In this paper, we review studies describing the heterogeneous virologic and immunologic progression following the initiation of HAART, and update findings obtained in the Multicenter AIDS Cohort Study that show that CD4 cell count and history of antiretroviral therapy at the time of initiation are independent determinants of response.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Egger M, Hirschel B, Francioli P, et al.: Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. BMJ 1997, 315:1194–1199.

    PubMed  CAS  Google Scholar 

  2. Hogg RS, O’Shaughnessy MV, Gataric N, et al.: Decline in deaths from AIDS due to new antiretrovirals. Lancet 1997, 349:1294.

    Article  PubMed  CAS  Google Scholar 

  3. Hogg RS, Heath KV, Yip B, et al.: Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998, 279:450–454.

    Article  PubMed  CAS  Google Scholar 

  4. Palella FJ, Jr., Delaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998, 338:853–860.

    Article  PubMed  Google Scholar 

  5. Detels R, Muñoz A, McFarlane G, et al.: Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. JAMA 1998, 280:1497–1503.

    Article  PubMed  CAS  Google Scholar 

  6. Ledergerber B, Egger M, Opravil M, et al.: Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 1999, 353:863–868. One of the earliest published findings that showed that most HAART users in a cohort supressed virus to less than 400 copies/mL within 6 months following initiation, and this suppression was related to treatment experience prior to HAART.

    Article  PubMed  CAS  Google Scholar 

  7. Jacobson LP, Yamashita TE, Detels R, et al.: Impact of potent antiretroviral therapy on the incidence of Kaposi’s sarcoma and non-Hodgkin’s lymphomas among HIV-1-infected individuals. J Acquir Immune Defic Syndr 1999, 21:S34-S41.

    PubMed  CAS  Google Scholar 

  8. Schapiro JM, Winters MA, Stewart F, et al.: The effect of highdose saquinavir on viral load and CD4+ T-cell counts in HIVinfected patients. Ann Intern Med 1996, 124:1039–1050.

    PubMed  CAS  Google Scholar 

  9. Casado JL, Perez-Elias MJ, Antela A, et al.: Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients. AIDS 1998, 12:F131-F135.

    Article  PubMed  CAS  Google Scholar 

  10. Hammer SM, Squires KE, Hughes MD, et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337:725–733.

    Article  PubMed  CAS  Google Scholar 

  11. Tarwater PM, Margolick JB, Jin J, et al.: Increase and plateau of CD4 T-cell counts in the 31/2 years after initiation of potent antiretroviral therapy. J Acquir Immune Defic Syndr 2001, 27:168–175.

    PubMed  CAS  Google Scholar 

  12. Clough LA, D’Agata E, Raffanti S, and Haas DW: Factors that predict incomplete virological response to protease inhibitor-based antiretroviral therapy. Clin Infect Dis 1999, 29:75–81.

    PubMed  CAS  Google Scholar 

  13. Wit FW, van Leeuwen R, Weverling GJ, et al.: Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons. J Infect Dis 1999, 179:790–798.

    Article  PubMed  CAS  Google Scholar 

  14. Dudley J, Jin S, Hoover D, et al.: The Multicenter AIDS Cohort Study: Retention after 9-1/2 years. Am J Epidemiol 1995, 142:323–330.

    PubMed  CAS  Google Scholar 

  15. Kaslow RA, Ostrow DG, Detels R, et al.: The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol 1987, 126(2):310–318.

    PubMed  CAS  Google Scholar 

  16. Giorgi JV, Cheng HL, Margolick JB, et al.: Quality control in the flow cytometric measurement of T-lymphocyte subsets: the Multicenter AIDS Cohort Study experience. Clin Immunol Immunopathol 1990, 55:173–186.

    Article  PubMed  CAS  Google Scholar 

  17. Schenker EL, Hultin LE, Bauer KD, et al.: Evaluation of a dual-color flow cytometry immunophenotyping panel in a multicenter quality assurance program. Cytometry 1993, 14:307–317.

    Article  PubMed  CAS  Google Scholar 

  18. Carpenter CCJ, Cooper DA, Fischl MA, et al.: Antiretroviral therapy in adults. Updated recommendations of the International AIDS Society - USA Panel. JAMA 2000, 283:381–390.

    Article  PubMed  CAS  Google Scholar 

  19. DHHS/Henry J: Kaiser Family Foundation Panel on Clinical Practices for the Treatment of HIV Infection: Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Accessible at http://hivatis.org.

  20. Jacobson LP, Li R, Phair J, et al.: Evaluation of effectiveness of highly active antiretroviral therapy (HAART) using biomarker-based equivalence of disease progression. Am J Epidemiol 2001, In press.

  21. Kleeberger CA, Phair JP, Strathdee SA, et al.: Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 2001, 26:82–92. Report from the MACS showing that host characteristics (race, income, use of the health care system) and treatment indices (number of drugs) predicted lower adherence among users of antiretroviral therapies.

    PubMed  CAS  Google Scholar 

  22. Bart PA, Rizzardi GP, Tambussi G, et al.: Immunological and virological responses in HIV-1-infected adults at early stage of established infection treated with highly active antiretroviral therapy. AIDS 2000, 14:1887–1897.

    Article  PubMed  CAS  Google Scholar 

  23. Yamashita, TE, Phair, JP, Muñoz, A, et al.: Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study. AIDS 2001, 15:735–746. Earlier analysis of short- and long-term HIV RNA and CD4 cell count response to HAART in the MACS that showed that best response was seen among those without experience to any of HAART’s components. Baseline CD4 cell count was a predictor of response, and age effects were restricted to early recovery of CD4 cells following HAART initiation.

    Article  PubMed  CAS  Google Scholar 

  24. Easterbrook PJ, Newson R, Ives N, et al.: Comparison of virologic, immunologic, and clinical response to five different initial protease inhibitor-containing and nevirapine-containing regimens. J Acquir Immune Defic Syndr 2001, 27:350–364.

    PubMed  CAS  Google Scholar 

  25. Erb P, Battegay M, Zimmerli W, et al.: Effect of antiretroviral therapy on viral load, CD4 cell count, and progression to acquired immunodeficiency syndrome in a community human immunodeficiency virus-infected cohort. Arch Intern Med 2000, 160:1134–1140.

    Article  PubMed  CAS  Google Scholar 

  26. Grabar S, Le Moing V, Goujard C, et al.: Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med 2000, 133:401–410.

    PubMed  CAS  Google Scholar 

  27. Gross R, Bilker WB, Friedman HM, and Strom BL: Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS 2001, 15:2109–2117.

    Article  PubMed  CAS  Google Scholar 

  28. Kitchen CM, Kitchen SG, Dubin JA, and Gottlieb MS: Initial virological and immunologic response to highly active antiretroviral therapy predicts long-term clinical outcome. Clin Infect Dis 2001, 33:466–472.

    Article  PubMed  CAS  Google Scholar 

  29. Le Moing V, Chene G, Carrieri MP, et al.: Clinical, biologic, and behavioral predictors of early immunologic and virologic response in HIV-infected patients initiating protease inhibitors. J Acquir Immune Defic Syndr 2001, 27:372–376.

    PubMed  Google Scholar 

  30. Lu W, Andrieu JM: HIV protease inhibitors restore impaired T-cell proliferative response in vivo and in vitro: a viralsuppression-independent mechanism. Blood 2000, 96:250–258.

    PubMed  CAS  Google Scholar 

  31. Mocroft A, Devereux H, Kinloch-de-Loes S, et al.: Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. Royal Free Centre for HIV Medicine. AIDS 2000, 14:1545–1552.

    Article  PubMed  CAS  Google Scholar 

  32. Pezzotti P, Pappagallo M, Phillips AN, et al.: Response to highly active antiretroviral therapy according to duration of HIV infection. J Acquir Immune Defic Syndr 2001, 26:473–479.

    PubMed  CAS  Google Scholar 

  33. Tortajada C, Garcia F, Plana M, et al.: Comparison of T-cell subsets’ reconstitution after 12 months of highly active antiretroviral therapy initiated during early versus advanced states of HIV disease. J Acquir Immune Defic Syndr 2000, 25:296–305.

    Article  PubMed  CAS  Google Scholar 

  34. Touloumi G, Paparizos V, Sambatakou H, et al.: Virological and immunological response to HAART therapy in a community-based cohort of HIV-1-positive individuals. HIV Clin Trials 2001, 2:6–16.

    Article  PubMed  CAS  Google Scholar 

  35. Phillips AN, Staszewski S, Weber R, et al.: HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA 2001, 286:2560–2567.

    Article  PubMed  CAS  Google Scholar 

  36. Marimoutou C, Chene G, Mercie P, et al.: Prognostic factors of combined viral load and CD4+ cell count responses under triple antiretroviral therapy, Aquitaine cohort, 1996–1998. J Acquir Immune Defic Syndr 2001, 27:161–167.

    PubMed  CAS  Google Scholar 

  37. Skowron G, Street JC, and Obee EM: Baseline CD4 + cell count, not viral load, correlates with virologic suppression induced by potent antiretroviral therapy. J Acquir Immune Defic Syndr 2001, 28:313–319.

    PubMed  CAS  Google Scholar 

  38. Jacobson LP, Gore ME, Strathdee SA, et al.: Therapy naivete in the era of potent antiretroviral therapy. J Clin Epidemiol 2001, 54:149–156.

    Article  PubMed  CAS  Google Scholar 

  39. Ahdieh L, Gange SJ, Greenblatt R, et al.: Selection by indication of potent antiretroviral therapy use in a large cohort of women infected with human immunodeficiency virus. Am J Epidemiol 2000, 152:923–933.

    Article  PubMed  CAS  Google Scholar 

  40. Bratt G, Karlsson A, Leandersson AC, et al.: Treatment history and baseline viral load, but not viral tropism or CCR-5 genotype, influence prolonged antiviral efficacy of highly active antiretroviral treatment. AIDS 1998, 12:2193–2202.

    Article  PubMed  CAS  Google Scholar 

  41. Brumme ZL, Chan KJ, Dong W, et al.: CCR5D32 and promoter polymorphisms are not correlated with initial virological or immunological treatment response. AIDS 2001, 15:2259–2266.

    Article  PubMed  CAS  Google Scholar 

  42. Guerin S, Meyer L, Theodorou I, et al.: CCR5 D32 deletion and response to highly active antiretroviral therapy in HIV-1-infected patients. AIDS 2000, 14:2788–2790.

    Article  PubMed  CAS  Google Scholar 

  43. Valdez H, Purvis SF, Lederman MM, et al.: Association of the CCR5D32 mutation with improved response to antiretroviral therapy. JAMA 1999, 282:734.

    Article  PubMed  CAS  Google Scholar 

  44. O’Brien TR, McDermott DH, Ioannidis JP, et al.: Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy. AIDS 2000, 14:821–826.

    Article  PubMed  CAS  Google Scholar 

  45. Lathey JL, Tierney C, Chang SYP, et al.: Associations of CCR5, CCR2, and stromal cell-derived factor 1 genotypes with human immunodeficiency virus disease progression in patients receiving nucleoside therapy. J Infect Dis 2001, 184:1402–1411.

    Article  PubMed  CAS  Google Scholar 

  46. Paredes R, Mocroft A, Kirk O, et al.: Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Arch Intern Med 2000, 160:1123–1132.

    Article  PubMed  CAS  Google Scholar 

  47. Miller V, Staszewski S, Sabin C, et al.: CD4 lymphocyte count as a predictor of the duration of highly active antiretroviral therapy-induced suppression of human immunodeficiency virus load. J Infect Dis 1999, 180:530–533.

    Article  PubMed  CAS  Google Scholar 

  48. Bahrani A, Ramaswamy R, and Oldfield EC, III: Effects of virologic rebound on CD4 cell counts. Clin Infect Dis 2001, 32:1231–1232.

    Article  PubMed  CAS  Google Scholar 

  49. Deeks SG, Hecht FM, Swanson M, et al.: HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS 1999, 13:F35-F43.

    Article  PubMed  CAS  Google Scholar 

  50. Deeks SG, Barbour JD, Martin JN, et al.: Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis 2000, 181:946–953. A study of a clinic cohort showing that although a direct relationship was observed between decreased HIV RNA following HAART initiation and increased CD4 cell counts, complete suppression of HIV RNA was not required for a rebound in CD4 cell counts.

    Article  PubMed  CAS  Google Scholar 

  51. Hejdeman B, Lenkei R, Leandersson AC, et al.: Clinical and immunological benefits from highly active antiretroviral therapy in spite of limited viral load reduction in HIV type 1 infection. AIDS Res Hum Retroviruses 2001, 17:277–286.

    Article  PubMed  CAS  Google Scholar 

  52. Mezzaroma I, Carlesimo M, Pinter E, et al.: Long-term evaluation of T-cell subsets and T-cell function after HAART in advanced stage HIV-1 disease. AIDS 1999, 13:1187–1193.

    Article  PubMed  CAS  Google Scholar 

  53. Wood E, Yip B, Hogg RS, et al.: Full suppression of viral load is needed to achieve an optimal CD4 cell count response among patients on triple drug antiretroviral therapy. AIDS 2000, 14:1955–1960.

    Article  PubMed  CAS  Google Scholar 

  54. DeHovitz JA, Kovacs A, Feldman JG, et al.: The relationship between virus load response to highly active antireroviral therapy and change in CD4 cell counts: A report from the Women’s Interagency HIV Study. J Infect Dis 2000, 182:1527–1530. Analysis of women initiating HAART in the Women’s Interagency HIV Study showing that greatest and continuous increase in CD4 cell count was achieved among women who sustained a decreased HIV RNA of 1 log or more in the 12 months following HAART initiation. CD4 cell increases were still observed among those with less optimal virologic response.

    Article  PubMed  CAS  Google Scholar 

  55. Mezzaroma I, Carlesimo M, Pinter E, et al.: Clinical and immunologic response without decrease in virus load in patients with AIDS after 24 months of highly active antiretroviral therapy. Clin Infect Dis 1999, 29:1423–1430.

    Article  PubMed  CAS  Google Scholar 

  56. Piketty C, Weiss L, Thomas F, et al.: Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen. J Infect Dis 2001, 183:1328–1335.

    Article  PubMed  CAS  Google Scholar 

  57. Greub G, Ledergerber B, Battegay M, et al.: Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000, 356:1800–1805. Analysis of HAART users in the Swiss HIV Cohort Study that showed that hepatitis C infection affected the CD4 cell count increase but not suppression of HIV RNA after the initiation of HAART.

    Article  PubMed  CAS  Google Scholar 

  58. Viard JP, Mocroft A, Chiesi A, et al.: Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. J Infect Dis 2001, 183:1290–1294. Report from the EuroSIDA study group showing that the increase in CD4 cell counts in the 3 years following HAART initiation occurred more rapidly among younger participants.

    Article  PubMed  CAS  Google Scholar 

  59. Pakker NG, Kroon ED, Roos MTL, et al.: Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. INCAS Study Group. AIDS 1999, 13:203–212.

    Article  PubMed  CAS  Google Scholar 

  60. Teixeira L, Valdez H, McCune JM, et al.: Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function. AIDS 2001, 15:1749–1756.

    Article  PubMed  CAS  Google Scholar 

  61. Douek DC, McFarland RD, Keiser PH, et al.: Changes in thymic function with age and during the treatment of HIV infection. Nature 1998, 396:690–695.

    Article  PubMed  CAS  Google Scholar 

  62. Haynes BF, Hale LP, Weinhold KJ, et al.: Analysis of the adult thymus in reconstitution of T lymphocytes in HIV-1 infection. J Clin Invest 1999, 103:453–460.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Room E7006, Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, 615 N. Wolfe Street, 21205, Baltimore, MD, USA

    Lisa P. Jacobson ScD

Authors
  1. Lisa P. Jacobson ScD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John P. Phair MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Traci E. Yamashita MS
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jacobson, L.P., Phair, J.P. & Yamashita, T.E. Virologic and immunologic response to highly active antiretroviral therapy. Curr Infect Dis Rep 4, 88–96 (2002). https://doi.org/10.1007/s11908-002-0072-5

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11908-002-0072-5

Keywords

Search

Navigation